Bachetti T, Comini L, Agnoletti L, Gaia G, Milanesi B, Curello S, Corti A, Ferrari R, Visioli O
Fondazione Salvatore Maugeri, Centro di Fisiopatologia Cardiovascolare, Gussago-Brescia.
Cardiologia. 1996 Apr;41(4):343-7.
Recently, an activation of the immune system has been demonstrated in congestive heart failure (CHF). Aim of this study was to evaluate the effects of CHF on the activation of alpha tumor necrosis factor (TNF-alpha), a pleiotropic cytokine. Since the soluble forms of the TNF membrane receptors, sTNF-RI and sTNF-RII, have been shown to modulate TNF-alpha biological activity, we determined antigenic TNF-alpha, bioactive TNF-alpha, sTNF-RI and sTNF-RII in 52 patients with varying degrees of CHF (NYHA functional class II, III, IV). The etiology of CHF was coronary artery disease in 51% of the patients, idiopathic dilated cardiomyopathy in 38% and valvular disease in 11%. All patients were treated with ACE-inhibitors, digoxin and inotropic agents. Antigenic TNF-alpha was significantly increased in NYHA functional class IV patients (from 12.1 +/- 7.6 to 38.5 +/- 12.4 pg/ml, p < 0.001) whereas cytotoxic activity was always under the detection limit of the assay (100 pg/ml). Soluble TNF receptors were significantly elevated in NYHA functional class IV patients: sTNF-RI increased from 1.27 +/- 0.48 to 4.54 +/- 2.11 ng/ml (p < 0.001) and sTNF-RII from 2.25 +/- 0.55 to 7.78 +/- 2.13 ng/ml (p < 0.001). The possible modulation of TNF-alpha biological activity by the soluble receptors was investigated by means of spiking experiments after addition of 625 pg/ml human recombinant TNF-alpha to each serum sample. The biological activity of the added TNF-alpha was significantly inhibited by the high levels of soluble receptors present in the sera of NYHA functional class IV patients (from 625 to 249 +/- 176 pg/ml, p < 0.001). The results show that TNF-alpha and its soluble receptors are activated in severe CHF. The high concentration of soluble TNF receptors circulating in CHF patients are likely to play a protective role against TNF-alpha biological activity.
最近,已有研究证实充血性心力衰竭(CHF)患者存在免疫系统激活。本研究旨在评估CHF对多效细胞因子α肿瘤坏死因子(TNF-α)激活的影响。由于TNF膜受体的可溶性形式sTNF-RI和sTNF-RII已被证明可调节TNF-α的生物学活性,我们测定了52例不同程度CHF(纽约心脏协会功能分级II、III、IV级)患者的抗原性TNF-α、生物活性TNF-α、sTNF-RI和sTNF-RII。CHF的病因在51%的患者中为冠状动脉疾病,38%为特发性扩张型心肌病,11%为瓣膜病。所有患者均接受了ACE抑制剂、地高辛和强心剂治疗。NYHA功能分级IV级患者的抗原性TNF-α显著升高(从12.1±7.6 pg/ml升至38.5±12.4 pg/ml,p<0.001),而细胞毒性活性始终低于检测限(100 pg/ml)。NYHA功能分级IV级患者的可溶性TNF受体显著升高:sTNF-RI从1.27±0.48 ng/ml升至4.54±2.11 ng/ml(p<0.001),sTNF-RII从2.25±0.55 ng/ml升至7.78±2.13 ng/ml(p<0.001)。通过向每个血清样本中添加625 pg/ml人重组TNF-α后的加标实验,研究了可溶性受体对TNF-α生物学活性的可能调节作用。NYHA功能分级IV级患者血清中高水平的可溶性受体显著抑制了添加的TNF-α的生物学活性(从625 pg/ml降至249±176 pg/ml,p<0.001)。结果表明,TNF-α及其可溶性受体在严重CHF中被激活。CHF患者循环中高浓度的可溶性TNF受体可能对TNF-α的生物学活性起到保护作用。